US Patent Issued to OPTI-THERA, LES LABORATOIRES SERVIER, VAL-CHUM on Nov. 11 for "Polygenic risk scores for predicting disease complications and/or response to therapy" (Canadian Inventors)

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,467,091, issued on Nov. 11, was assigned to OPTI-THERA INC. (Montreal, Canada), LES LABORATOIRES SERVIER (Suresnes, France) and VAL-CHUM LP (Quebec, Canada).

"Polygenic risk scores for predicting disease complications and/or response to therapy" was invented by Pavel Hamet (Montreal, Canada) and Johanne Tremblay (Montreal, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods, processes, and systems for predicting a subject's disease complications and/or response to therapy are described herein. The methods generally comprise genotyping or receiving genotyping information from the subject at a plurality of risk alleles associated with the diseas...